Bavarian Nordic says it has gathered between five and nine term sheets from potential partners for its experimental prostate cancer vaccine. The company's business development chief, Juergen Langhaerig, told a conference that the mix of international companies included some of the "largest companies in the world, the top 10, and some are mid-sized, fast-growing companies." Story